Study backs efficacy, cost-effectiveness of diabetes prevention efforts

04/1/2012 | Endocrine Today

Participants assigned to a lifestyle intervention program or metformin treatment designed to help prevent or delay type 2 diabetes onset attained well-being scores of 6.81 and 6.69, respectively, compared with only 6.67 in those who had placebo treatment, a study in Diabetes Care revealed. Researchers also found that lifestyle intervention and metformin treatment resulted in higher cumulative direct medical costs, but showed greater efficacy than placebo therapy.

View Full Article in:

Endocrine Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT